The Effects of Resveratrol Treatment on Bcl-2 and Bax Gene Expression in Endometriotic Compared with Non-Endometriotic Stromal Cells

Roya Kolahdouz‐Mohammadi, Roya Kolahdouz-Mohammadi, Ali-Akbar Delbandi, Ali‐Akbar Delbandi, Sepideh Khodaverdi, Soheila Arefi, Tahereh Arablou, Farzad Shidfar
Iranian journal of public health · 2020 · vol. 49(8) , pp. 1546–1554 · doi:10.18502/ijph.v49i8.3900 · PMID:33083332 · W3046812148
article OA: gold CC0 ⤵ 14 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Resveratrol treatment increased Bcl-2 and the Bcl-2/Bax ratio in control and eutopic endometriotic stromal cells, but had limited effects on ectopic endometriotic stromal cells.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated the effects of resveratrol on apoptosis-related gene expression by measuring Bcl-2 and Bax in endometriotic versus non-endometriotic stromal cells. Stromal cells were compared at the gene-expression level after resveratrol treatment to determine whether resveratrol differentially modulates pro- and anti-apoptotic signaling between these cell types. The paper reports that resveratrol altered Bcl-2 and Bax expression in a way that differed between endometriotic and non-endometriotic stromal cells, consistent with modulation of apoptosis-related pathways. The key limitation is that the work is based on stromal cell gene-expression assays rather than in vivo functional outcomes. This paper is centrally about endometriosis — it examines how resveratrol changes Bcl-2 and Bax expression in endometriotic versus non-endometriotic stromal cells.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Background: We aimed to examine resveratrol effects on gene expression of Bcl-2, Bax and Bcl-2/Bax ratio in endometrial stromal cells derived from women with and without endometriosis. Methods: Endometrial tissues were obtained from 40 endometriotic patients and 15 non-endometriotic controls undergoing laparoscopic surgery or hysterectomy in the gynecology ward of Rassoul Akram Hospital, Tehran, Iran from 2015 to 2017. After the enzymatic digestion, eutopic (EuESCs) and ectopic (EESCs) endometrial stromal cells from patients with endometriosis as well as endometrial stromal cells from non-endometriotic controls (CESCs) were treated with or without resveratrol (100 µM) and the levels of Bcl-2, Bax and Bcl-2/Bax gene expression ratio in the cells from all origins were examined at 6, 24 and 48 h post-treatment by real-time PCR. Results: Resveratrol treatment increased Bcl-2 expression in CESCs at 24 and 48 h and in EuESCs at 48 h (P<0.05), but had no significant effects on the expression of this gene in EESCs. On the other hand, resveratrol treatment increased Bax expression in EuESCs at 6 h and decreased its expression in EESCs at 48 h (P<0.05). Regarding the Bcl-2/Bax gene expression ratio, resveratrol treatment increased Bcl-2/Bax gene expression ratio in CESCs and EuESCs at 48 h (P<0.01). However, this treatment had no significant differential effect on Bcl-2 and Bcl-2/Bax gene expression ratio between CESCs and EuESCs at 48 h. Conclusion: Resveratrol treatment significantly increased Bcl-2/Bax gene expression ratio in EuESCs and CESCs but had no significant effect in EESCs.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (42)

Cited by (14)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:36.268089+00:00
License: CC0 · commercial use OK